Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Classic Hodgkin lymphoma (cHL) exhibits an immunosuppressed tumor microenvironment.
• Elevated PD-L1 expression on Hodgkin Reed Sternberg (HRS) cells, driven by 9p24.1 amplification, is a key feature.
• Immune checkpoint inhibitors targeting PD-1/PD-L1 are effective in relapsed/refractory cHL.

Purpose of the Study:

• To review the efficacy and challenges of immune checkpoint inhibitors in cHL.
• To discuss ongoing combination strategies and future research directions.
• To critically evaluate the use of checkpoint inhibitors in the frontline setting for cHL.

Main Methods:

• Literature review of studies on immune checkpoint inhibitors in cHL.
• Analysis of response rates, durability, and relapse patterns.
• Discussion of unanswered questions regarding response evaluation, therapy modification, endpoints, and biomarkers.

Main Results:

• Immune checkpoint inhibitors achieve 70-80% response rates in relapsed/refractory cHL, often with durable responses.
• Despite high response rates, a significant proportion of patients still experience relapse.
• Combination strategies involving chemotherapy, antibody-drug conjugates (ADCs), and other immunotherapies are under investigation.

Conclusions:

• Immune checkpoint inhibitors represent a significant advancement in cHL treatment.
• Further research is essential to address challenges such as defining optimal response evaluation, tailoring therapy, validating endpoints, and identifying predictive biomarkers.
• A critical approach is necessary when considering checkpoint inhibitors in the frontline setting for cHL.